Literature DB >> 19349727

Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly.

Merih Baykan1, Cihangir Erem, Omer Gedikli, Arif Hacihasanoglu, Turan Erdogan, Mustafa Kocak, Sahin Kaplan, Levent Korkmaz, Sükrü Celik.   

Abstract

OBJECTIVE: The aim of this study was to assess flow-mediated dilatation (FMD) of the brachial artery in patients with acromegaly. SUBJECTS AND METHODS: We prospectively evaluated 25 patients with acromegaly (14 females, 11 males; aged 42 +/- 12 years; growth hormone (GH) levels 34 +/- 14 ng/ml) and 27 control subjects (15 females, 12 males; aged 45 +/- 8 years; GH levels 3 +/- 1.5 ng/ml). The patients and controls were matched for age, gender, body mass index, cigarette smoking, blood pressure, lipid levels, diabetes mellitus, hypertension, and its duration. Endothelial function, measured as FMD of the brachial artery using ultrasound, was calculated in the 2 groups. The endothelial function was evaluated by assessing 1-min postischemic FMD of the brachial artery.
RESULTS: The FMD was lower in patients with acromegaly (9.97 +/- 3.5%) than in controls (16.1 +/- 3.4%), and the difference was statistically significant (p = 0.0001).
CONCLUSION: Endothelial dysfunction may develop in the preclinical phase of atherosclerosis in patients with acromegaly. Endothelium-dependent FMD may be impaired in acromegalic patients, and measurement of endothelial function may identify high-risk individuals earlier. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19349727     DOI: 10.1159/000204355

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  8 in total

1.  Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.

Authors:  Marianna Yaron; Elena Izkhakov; Jessica Sack; Ibrahim Azzam; Etty Osher; Karen Tordjman; Naftali Stern; Yona Greenman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

Review 2.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.

Authors:  Cigdem Ozkan; Alev Eroglu Altinova; Ethem Turgay Cerit; Cagri Yayla; Asife Sahinarslan; Duygu Sahin; Aylin Sepici Dincel; Fusun Balos Toruner; Mujde Akturk; Metin Arslan
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 4.  Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.

Authors:  Matteo Parolin; Francesca Dassie; Chiara Martini; Roberto Mioni; Lucia Russo; Francesco Fallo; Marco Rossato; Roberto Vettor; Pietro Maffei; Claudio Pagano
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 5.  The risks of overlooking the diagnosis of secreting pituitary adenomas.

Authors:  Thierry Brue; Frederic Castinetti
Journal:  Orphanet J Rare Dis       Date:  2016-10-06       Impact factor: 4.123

Review 6.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

Review 7.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

8.  Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.

Authors:  Xuemei Yu; Peihong Chen; Hongtao Wang; Tong Zhu
Journal:  Med Princ Pract       Date:  2012-09-04       Impact factor: 1.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.